11/29/11 No new buys on tools/Dx since summer meltdown and Illumina (ILMN) miss.
Mid-cap biopharms are up 1.6% as of mid-day. Mixed tape in Dx and Tools with winners BLUD, ILMN, NEOG and SQNM; losers are down less than 1%. Qiagen(QGEN) still weak.
6/6/11 GenProbe (GPRO) near peak value with buy-out from Novartis (NVS) likely. Take some profits on CSII.
Immucor (BLUD $21.40) is trying to lose its “laggard” status by beating sales and profit guidance. The Company earned $22.7M on $83.3M in sales for teh quarter ended Feb. 28,2011. Profit grew 14% and sales grew 4%. The stock was up 7% after hours.